Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
4.310
+0.220 (5.38%)
Nov 22, 2024, 4:00 PM EST - Market closed
Alto Neuroscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -57.45 | -36.31 | -27.71 | -9.19 |
| Depreciation & Amortization | 0.44 | 0.37 | 0.34 | 0.15 |
| Loss (Gain) From Sale of Assets | 0.14 | 0.14 | - | - |
| Stock-Based Compensation | 6.67 | 2.89 | 1.76 | 0.23 |
| Other Operating Activities | 1.46 | 0.15 | 0.63 | 0.13 |
| Change in Accounts Receivable | 0.01 | 0.33 | 1.16 | -1.29 |
| Change in Accounts Payable | 0.5 | -0.63 | 1.01 | 0.46 |
| Change in Other Net Operating Assets | 2.3 | -0.39 | 2.42 | 0.26 |
| Operating Cash Flow | -45.93 | -33.45 | -20.39 | -9.26 |
| Capital Expenditures | -1.92 | -0.47 | -0.73 | -0.68 |
| Investing Cash Flow | -1.92 | -0.47 | -0.73 | -0.68 |
| Long-Term Debt Issued | - | - | 9.83 | - |
| Net Debt Issued (Repaid) | - | - | 9.83 | - |
| Issuance of Common Stock | 137.75 | 0.18 | 0.04 | 0.01 |
| Other Financing Activities | -3.97 | -2.05 | -0.34 | -0.21 |
| Financing Cash Flow | 178.77 | 68.13 | 43.79 | 31.69 |
| Foreign Exchange Rate Adjustments | -0.01 | -0.01 | -0.02 | -0.05 |
| Net Cash Flow | 130.91 | 34.2 | 22.64 | 21.7 |
| Free Cash Flow | -47.85 | -33.92 | -21.13 | -9.94 |
| Free Cash Flow Margin | - | - | - | -4734.29% |
| Free Cash Flow Per Share | -2.54 | -9.09 | -6.13 | -4.12 |
| Cash Interest Paid | 1 | 0.91 | - | - |
| Levered Free Cash Flow | -32.37 | -23.45 | -12.3 | - |
| Unlevered Free Cash Flow | -31.49 | -22.6 | -12.3 | - |
| Change in Net Working Capital | -2.92 | 1.76 | -4.57 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.